Search results
Results from the WOW.Com Content Network
Pegaspargase can be administered either via an intravenous infusion or a intramuscular injection. [6] Known side effects include allergic reactions, coagulopathy, high blood sugar, affecting liver function, pancreas inflammation, and blood clots in the brain. [6] There is no data regarding the usage of pegaspargase during pregnancy. [7]
Subjects received either calaspargase pegol-mknl intravenously every 3 weeks for 10 doses or pegaspargase intravenously every 2 weeks for 15 doses during the second phase. [8] The benefit of calaspargase pegol-mknl was assessed by measuring the activity level of asparaginase in the blood on Days 7, 11, 18, 25, and 32 of the first phase and ...
Common side effects when used by injection include allergic reactions, pancreatitis, blood clotting problems, high blood sugar, kidney problems, and liver dysfunction. [6] Use in pregnancy may harm the baby. [9] As a food it is generally recognized as safe. [7]
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
CagriSema’s side effects appeared to be similar to other drugs in the GLP-1 class; the company said the most common ones were gastrointestinal, with the “vast majority” mild to moderate and ...
Polyethylene glycol. PEGylation (or pegylation) is the process of both covalent and non-covalent attachment or amalgamation of polyethylene glycol (PEG, in pharmacy called macrogol) polymer chains to molecules and macrostructures, such as a drug, therapeutic protein or vesicle, which is then described as PEGylated.
The side effects of the administration of the chemotherapeutic agents used in hyper-CVAD are complex, and are often dependent on the overall health of the patient. Hematologic and immune system The majority of patients will experience a degree of pancytopenia , including anaemia , thrombocytopenia , and leukopenia , due to the myelosuppressive ...
Side effects of PARP inhibitor treatment for cancer may include neutropenia, and a risk of anaemia. [25] People who take this medication also commonly report fatigue. [ 25 ] The toxicity profile of PARP inhibitors when treating cancer has not been found to be more serious than chemotherapy agents, however, further research is needed to ...